Sialophorin, a surface sialoglycoprotein defective in the Wiskott-Aldrich syndrome, is involved in human T lymphocyte proliferation.
Open Access
- 1 May 1987
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 165 (5) , 1383-1392
- https://doi.org/10.1084/jem.165.5.1383
Abstract
The mAb L10 was used to determine the distribution and the function of sialophorin, the heavily glycosylated surface molecule that is deficient/defective in lymphocytes of patients with the X-linked immunodeficiency Wiskott-Aldrich syndrome. Dual-parameter FACS analysis indicated that sialophorin is expressed on CD4+ and CD8+ lymphocytes, on a subpopulation of peripheral blood B lymphocytes, on all thymocytes, and on a subpopulation of bone marrow cells. Functional studies demonstrated that L10 mAb stimulates the proliferation of peripheral blood T lymphocytes as measured by stimulation of [3H]thymidine incorporation. The time course and magnitude of increased [3H]thymidine incorporation by T lymphocytes in response to L10 mAb paralleled that induced by anti-CD3 mAb. Effective stimulation was dependent on the presence of monocytes and the Fc portion of L10 mAb. Stimulation of lymphocytes by L10, like stimulation by anti-CD3 mAb, involves increased expression of 4F2, HLA-DR, and IL-2-R. These observations suggest that sialophorin functions in T cell activation.This publication has 24 references indexed in Scilit:
- Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen).The Journal of Experimental Medicine, 1985
- The large sialoglycoprotein of human lymphocytes. I. Distribution on T and B lineage cells as revealed by a monospecific chicken antibodyEuropean Journal of Immunology, 1984
- The Primary ImmunodeficienciesNew England Journal of Medicine, 1984
- Characterization of a human lymphocyte surface sialoglycoprotein that is defective in Wiskott-Aldrich syndrome.The Journal of Experimental Medicine, 1984
- Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of C3bi binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mol).Journal of Clinical Investigation, 1983
- BONE MARROW TRANSPLANTATION IN THE WISKOTT-ALDRICH SYNDROMETransplantation, 1982
- A monoclonal antibody (MMA) thet identifies a differentiation antigen on human myelomonocytic cellsClinical Immunology and Immunopathology, 1982
- Complete Correction of the Wiskott-Aldrich Syndrome by Allogeneic Bone-Marrow TransplantationNew England Journal of Medicine, 1978
- Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: Differentiation antigens of rat lymphocytesCell, 1977
- BONE-MARROW TRANSPLANTATION IN A PATIENT WITH THE WISKOTT-ALDRICH SYNDROMEThe Lancet, 1968